IVF Hartmann Holding AG — Cyborg Score 7/10

Solid
Medical Instruments & Supplies / Healthcare Consumer Products

Strategic Profile

The company operates across four segments: wound care, incontinence management, infection management, and other group activities. Its primary clients include hospitals, doctors, surgery centers, care centers, pharmacies, drugstores, wholesalers and corporate medical centers. The company operates as a subsidiary of Paul Hartmann Finance B.V.

Cyborg Score Rationale

IVF Hartmann demonstrates solid fundamentals as an established medical supplies provider with 150+ years of heritage and international reach. The company maintains reasonable profitability metrics with a PE ratio of 17.61 and dividend yield of 4.53%, though limited public data on growth trajectory constrains the assessment.

Top Insights

  • Legacy Swiss medical supplies company with 154-year operational history and strong institutional clientele across hospitals and healthcare facilities
  • Operates within subsidiary structure of Paul Hartmann Finance, indicating private equity backing and potential for operational optimization
  • Dividend yield of 4.53% suggests focus on cash returns to shareholders, appealing to income investors
  • Limited market cap (~CHF 324-400M) indicates niche positioning in specialized medical/hygiene products rather than mass-market competition

Named Competitors

  • Medical Devices & Supplies — Large-cap diversified medical device manufacturer
  • Healthcare Consumer Products — Scandinavia-based hygiene products competitor
  • Medical Supplies Distribution — Parent company and direct competitor in medical supplies

Open the full interactive IVF Hartmann Holding AG report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →